Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PVLA vs DSGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PVLA Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 2–3 Matrix Metrics)

PVLA Overall Winner 6-Pillar Tally: PVLA 2 – 1 DSGN (3 Tie) Matrix Metrics: PVLA 2 – 3 DSGN

As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). PVLA carries a Unified Composite Score of 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. PVLA 48.9/100 HOLD), PVLA captures the overall institutional head-to-head verdict (2–3 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: PVLA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PVLA vs DSGN
PVLA NASDAQ Head-to-Head Winner
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 38.0 Fund 52.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.0%) with fading momentum, RSI 47
RSI-14: 47.4 · SMA20: $147.90 · SMA50: $143.31
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
TTM Revenue $33,000
Forward P/E N/M
Beta / 30D Vol 1.32β · 61% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 55.0 Fund 57.0 Flow 63.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.7%), weak momentum, RSI 40
RSI-14: 40.4 · SMA20: $10.53 · SMA50: $11.58

6-Pillar Scorecard Institutional Category Breakdown (PVLA 2 – 1 DSGN)

Columns: Metric · PVLA · DSGN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $33,000
Market Cap $2.2B $677.5M
3. Profitability & Quality DSGN
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -63.4% -36.9%
4. Balance Sheet & Cash Flow PVLA
Cash Generation (TTM) -$43M -$59M
Cash Flow Margin N/A N/A
Net Cash / Leverage $193M Net Cash $13M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PVLA
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 47.9% (2nd %ile) 92.0% (13th %ile)
Put/Call OI Skew 3.82x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PVLA (2) vs DSGN (3)
Institutional Metric PVLA DSGN Criterion Row Edge
Market Capitalization
Scale
$2.2B $677.5M Larger Scale PVLA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-63.4% -36.9% Higher ROE DSGN
52-Week Range Position
Momentum
68% ($72–$180) 30% ($7–$17) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.66β · 75% Vol 1.32β · 61% Vol Lower Realized Risk DSGN
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite DSGN
Trailing 12M Revenue (USD)
Operating Scale
N/A $33,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M ($193M Net Cash) -$59M ($13M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +24.15 pp
PVLA: +20.56% · DSGN: -3.59%
3M Horizon PVLA +31.33 pp
PVLA: -3.58% · DSGN: -34.91%
6M Horizon PVLA +45.16 pp
PVLA: +38.06% · DSGN: -7.1%
1Y Horizon PVLA +39.37 pp
PVLA: +80.16% · DSGN: +40.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PVLA Revenue DSGN Revenue PVLA Op. Margin DSGN Op. Margin Margin Leader
FY2016 $10M N/A -390.3% N/A PVLA
FY2017 $30M N/A -57.7% N/A PVLA
FY2018 $30M N/A -113.1% N/A PVLA
FY2019 $40M N/A -62.2% N/A PVLA
FY2020 $30M $0M -115.7% -3685.8% PVLA
FY2021 $30M N/A -165.0% N/A PVLA
FY2022 $30M N/A -167.8% N/A PVLA
FY2023 $40M N/A -27.7% N/A PVLA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DSGN BREAKDOWN
139d in phase · OBV NEUTRAL
Current IV 92.0%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DSGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PVLA vs DSGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). PVLA carries a Unified Composite Score of 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas DSGN carries 49.8/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DSGN currently prints a higher short-term Unified Composite Score (49.8/100 HOLD vs. PVLA 48.9/100 HOLD), PVLA captures the overall institutional head-to-head verdict (2–3 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: PVLA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4); meanwhile DSGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PVLA and DSGN split Growth & Scale metrics: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DSGN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2016 to FY2023), PVLA cumulative revenue shifted +300.0% while DSGN shifted N/A. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DSGN.

PVLA and DSGN trade at balanced relative valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus DSGN (-36.9% ROE) capital efficiency.

In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.